Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 8 for:    lithoplasty

Shockwave Coronary Lithoplasty Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02758379
Recruitment Status : Completed
First Posted : May 2, 2016
Last Update Posted : July 21, 2017
Sponsor:
Collaborators:
Yale Cardiovascular Research Group
Massachusetts General Hospital
Pacific Clinical Research Group
Information provided by (Responsible Party):
Shockwave Medical, Inc.

Brief Summary:
The objective of this clinical trial is to study the early safety and feasibility of the Shockwave Coronary Lithoplasty System. To demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, de novo coronary lesions.

Condition or disease Intervention/treatment Phase
Coronary Stenosis Device: Shockwave Coronary Lithoplasty System Not Applicable

Detailed Description:
Prospective, non-randomized, single center First In Human (FIH) trial for treatment of stenotic calcified coronary lesions with the Shockwave Lithoplasty System. Patients will be enrolled and consented in the study based on history and in some instances an angiogram obtained prior to the study. The study is designed to demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, coronary arteries. Subjects will be prepared for PCI per the institution's standard protocol. Medications will be administered per the treatment protocol. Femoral access will be obtained using a 6F access sheath, and guiding catheter placed at the ostia of the right or left coronary artery. Baseline angiography of the culprit lesion will be performed prior to placement of a 0.014" guide wire. Baseline and either IVUS or OCT will be performed to determine the Maximum Lumen Area (MLA), percent stenosis, and volumetric lesion assessment. Baseline angiography will be performed to determine lesion length, % stenosis and reference vessel diameter. The investigational device will be prepped per the IFU and positioned at the target lesion. The distal end of the balloon catheter will be connected to the patient cable. The balloon catheter will be inflated to 4 atm and the investigator will deliver 10 pulses for 20 seconds. The balloon will then be inflated to reference vessel diameter and then deflated to reestablish flow and complete one treatment cycle. The treatment cycle will then be repeated. Angiography and either IVUS or OCT will be repeated for the treated lesion.. A coronary stent will be deployed at the site of treatment. Angiography and either IVUS or OCT will be performed following stent placement. Patients will be followed through discharge and at 30 and 180 days. A subset of up to five (5) subjects will receive an angiographic assessment at the 180 day follow up visit, per the Sponsor's discretion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Safety and Feasibility Study of the Shockwave Coronary Lithoplasty™ System in Coronary Arteries
Study Start Date : July 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : March 2016

Arm Intervention/treatment
Experimental: Shockwave Coronary Lithoplasty System
Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
Device: Shockwave Coronary Lithoplasty System
Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries




Primary Outcome Measures :
  1. Safety - Acute, as indicated by number of subjects that do not experience death following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  2. Safety - Acute, as indicated by number of subjects that do not experience tamponade following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  3. Safety - Acute, as indicated by number of subjects that do not experience dissection, occlusion or perforation of the coronary artery that requires additional intervention to treat besides stenting following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  4. Safety - Acute, as indicated by number of subjects that do not experience aneurysm following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  5. Safety - Acute, as indicated by number of subjects that do not experience MI (CPK > 5 x uln) following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  6. Safety - Acute, as indicated by number of subjects that do not experience cardiogenic shock following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  7. Safety - Acute, as indicated by number of subjects that do not experience distal embolization compromising blood flow, and requiring intervention following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  8. Safety - Acute, as indicated by number of subjects that do not experience blood transfusion due to excessive blood loss following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  9. Safety - Acute, as indicated by number of subjects that do not experience stroke following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  10. Safety - 30 days (Number of subjects without any procedure and/or device related adverse events) [ Time Frame: 30 days post procedure ]
  11. Safety - 30 days (Number of subjects without target lesion revascularization (TLR) [ Time Frame: 30 days post procedure ]
  12. Safety - 30 days (Number of subjects without groin complications) [ Time Frame: 30 days post procedure ]
  13. Safety - 180 days (Number of subjects without any procedure and/or device related adverse events) [ Time Frame: 180 days post procedure ]
  14. Safety - 180 days (Number of subjects without any target lesion revascularization (TLR)) [ Time Frame: 180 days post procedure ]
  15. Performance - Acute technical success of the device [ Time Frame: Post-procedure (within 24 hours following procedure) ]
    • Successful delivery of the device and administration of lithotripsy-enhanced low pressure balloon dilation to the target lesion
    • Residual stenosis of ≤50% of the reference vessel size of the target lesion assessed by angiography and either IVUS or OCT.
    • Successful access of the treatment site with a coronary stent

  16. Safety - Acute, as indicated by number of subjects that do not experience ventricular arrhythmic event requiring intervention to re-establish normal rhythm following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. At least 18 years of age and able to give informed consent.
  2. Patients in Sinus Rhythm.
  3. Patients with significant (> 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI.
  4. Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel or prasugrel). For 1 year and single therapy for life.
  5. Patient is able and willing to comply with all assessments in the study.
  6. Stenosis of LAD, RCA or LCX artery ≥50% in a reference vessel of 2.5mm-3.5 mm diameter and ≤ 22 mm length, as assessed by two orthogonal angiographic views.
  7. Calcification with parallel calcium at least 50% the length of the lesion.
  8. At the time of the procedure the subject is in Sinus Rhythm.
  9. Single lesions per vessel.
  10. Ability to pass a 0.014" guide wire across the lesion.

Exclusion Criteria:

  1. Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices.
  2. Additional planned coronary interventions for a non-target lesion within 180 days of the study procedure.
  3. Left ventricular ejection fraction < 40%
  4. Patients refusing or not candidates for emergency coronary artery bypass grafting (CABG) surgery
  5. Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
  6. Patients who are not candidates for dual anti-platelet therapy for 30 days and chronic single anti-platelet therapy
  7. Severe renal failure with creatinine >2.5 mg/dL
  8. Untreated pre-procedural hemoglobin <10 g/dL
  9. Coagulopathy manifested by platelet count <100,000 or International Normalized ratio (INR) >1.7 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment)
  10. Patients in cardiogenic shock
  11. Acute myocardial infarction (MI) within the past one (1) month, and/or elevated CPK (and abnormal Troponin-I) at the time of enrollment
  12. Patients with a life expectancy of less than 1 year
  13. Target main branch vessel < 2.5 mm in diameter
  14. Target main branch lesion > 22 mm in length
  15. Chronic Total Occlusion (CTO).
  16. Previous stent procedure within 10 mm of target lesion
  17. Prior PCI procedure within the last 6 months.
  18. Target lesion demonstrating severe dissection prior to planned use of the Shockwave device
  19. Unprotected Left Main diameter stenosis ≥ 50%
  20. Visible thrombus (by angiography) at target lesion site
  21. Patient has active systemic infection
  22. Patient with an externally-connected intracardiac catheter or pacemaker.
  23. Patient with an implantable pacemaker or defibrillator.
  24. Patient has connective tissue disease (e.g., Marfan's syndrome)
  25. Patient has a hypercoagulable disorder.
  26. Patient has allergy to imaging contrast media for which they cannot be pre-medicated.
  27. Evidence of aneurysm or acute thrombus in target vessel.
  28. Patients with prior sternotomy as a result of thoracic surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02758379


Locations
Layout table for location information
Australia, Victoria
St. Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
Sponsors and Collaborators
Shockwave Medical, Inc.
Yale Cardiovascular Research Group
Massachusetts General Hospital
Pacific Clinical Research Group
Investigators
Layout table for investigator information
Principal Investigator: Robert Whitbourn, M.D. St. Vincent Hospital, Melbourne, Australia

Layout table for additonal information
Responsible Party: Shockwave Medical, Inc.
ClinicalTrials.gov Identifier: NCT02758379     History of Changes
Other Study ID Numbers: TD 0200
First Posted: May 2, 2016    Key Record Dates
Last Update Posted: July 21, 2017
Last Verified: July 2017

Keywords provided by Shockwave Medical, Inc.:
coronary artery disease
calcified lesions
lithotripsy

Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Stenosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases